Papillomaviruses: General Features of Human Viruses

Encyclopedia of Virology

Volumn , Issue , 2008, Pages 8-18

  Orth, G ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Anogenital cancer; Asymptomatic infections; Carcinoma of the uterine cervix; Cervical cancer prevention; Cervical intraepithelial neoplasia; Differentiation dependent replication; E6; E7 oncoproteins; Epidermodysplasia verruciformis; High risk human papillomavirus types; HPV vaccines; Persistent infections; Sexually transmitted infections; Spontaneous regression; Virus like particles; Warts

Indexed keywords

EID: 84867456290     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012374410-4.00457-X     Document Type: Chapter

References (15)

1. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology 2002, 55:244-265.
2. Bosch F.X., Schiffman M., Solomon D. Future directions in epidemiologic and preventive research on human papillomaviruses and cancer. Journal of the National Cancer Institute Monographs 2003, 31:1-130.
3. Papillomavirus Research: From Natural History to Vaccines and Beyond 2006, Caister Academic Press, Wymondham, UK. M.S. Campo (Ed.).
4. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur Hausen H. Classification of papillomaviruses. Virology 2004, 324:17-27.
5. Frazer I.H., Thomas R., Zhou J., et al. Potential strategies utilised by papillomaviruses to evade host immunity. Immunological Reviews 1999, 168:131-141.
6. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 2006, 367:1247-1255.
7. Howley P.M., Lowy D.R. Papillomaviruses. Fields Virology 2007, 2229-2354. Wolters Kluwer/Lippincott Williams and Wilkins, Philadelphia, PA. 5th edn. D.M. Knipe, P.M. Howley, D.E. Griffin (Eds.).
8. IARC Monographs on the evaluation of carcinogenic risks to humans, Vol. 90: Human Papillomaviruses 2006, IARC, International Agency for Research on Cancer Press, Lyon.
9. Münger K., Baldwin A., Edwards K.M., et al. Mechanisms of human papillomavirus-induced oncogenesis. Journal of Virology 2004, 78:11451-11460.
10. Munoz N., Bosch F.X., de Sanjosé S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 2003, 348:518-527.
11. Narechania A., Chen Z., DeSalle R., Burk R.D. Phylogenetic incongruence among oncogenic genital alpha human papillomaviruses. Journal of Virology 2005, 79:15503-15510.
12. Orth G. Genetics of epidermodysplasia verruciformis: Insights into host defense against papillomaviruses. Seminars in Immunology 2006, 18:362-374.
13. Orth G., Jablonska S. Papillomaviruses: Part two. Clinics in Dermatology 1997, 15:303-470.
14. Villa L.L., Costa R.L.R., Andrade R.P., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer 2006, 95:1459-1466.
15. zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nature Reviews Cancer 2002, 2:342-350.